George G. Aubrey, Jr. is a seasoned entrepreneur with a diverse background spanning golf course development, financial services, medical research, and innovative laser technologies. His entrepreneurial journey began in 1965 with the design and construction of Aubrey’s Dubbs Dred Golf Course, Inc., where he currently serves as President. The course earned recognition in Golf Digest’s “Best Places to Play in North America and the Islands” for four consecutive years. A retired member of the Professional Golfers Association (PGA), George combines his passion for innovation with a commitment to excellence in every endeavor.
In addition to his achievements in golf, George is the founder and President of Aubrey Financial Services, Inc., an insurance and securities brokerage firm specializing in creative estate planning and tax-advantaged wealth preservation. His work integrates legal, accounting, and TPA associations to deliver comprehensive financial solutions. George also played a pivotal role in organizing and managing several medical research laboratories, along with being a significant investor in medical device companies.
In the late 1990s, George and his friend Bob Werra turned their attention to laser eye surgery, particularly for hyperopia (farsightedness). Unimpressed by existing solutions, Bob founded NTK Enterprises, collaborating with top doctors and scientists to develop a superior laser technology. Through continuous innovation, the Opti-K™ laser was born, offering a groundbreaking, noninvasive treatment for presbyopia (age-related loss of near vision).
In 2021, George partnered with Nancy Werra to drive the commercialization of Opti-K™. He assembled a world-class team of scientists, medical experts, regulatory specialists, and financial consultants to establish VIS LLC, acquiring the patents and assets of NTK Enterprises. Under George’s leadership, VIS successfully completed the FDA Phase I and II feasibility studies, and on April 20, 2023, the FDA granted an Investigational Device Exemption (IDE) to proceed with Phase III (pivotal study), the final stage of clinical trials.
With decades of experience and a track record of success, George G. Aubrey continues to lead in innovation and entrepreneurship, shaping the future of vision care and beyond.
